Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Accumulated Expenses (2017 - 2025)

Cue Biopharma's Accumulated Expenses history spans 9 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 41.51% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, down 41.51%, while the annual FY2024 figure was $1.8 million, 56.2% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $1.9 million at Cue Biopharma, up from $1.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $5.2 million in Q1 2024 and bottomed at $1.5 million in Q2 2025.
  • The 5-year median for Accumulated Expenses is $3.6 million (2022), against an average of $3.5 million.
  • The largest annual shift saw Accumulated Expenses soared 83.19% in 2024 before it plummeted 66.73% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $4.6 million in 2021, then decreased by 23.07% to $3.6 million in 2022, then increased by 16.4% to $4.1 million in 2023, then plummeted by 56.2% to $1.8 million in 2024, then rose by 3.26% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Accumulated Expenses are $1.9 million (Q3 2025), $1.5 million (Q2 2025), and $4.2 million (Q1 2025).